Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
78%(7 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
1
9%
Ph phase_2
3
27%
Ph phase_3
2
18%
Ph phase_4
4
36%

Phase Distribution

0

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
4(40.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(1)
Other(1)

Detailed Status

Completed9
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (30.0%)
Phase 32 (20.0%)
Phase 44 (40.0%)
N/A1 (10.0%)

Trials by Status

completed982%
unknown19%
terminated19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_4

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

NCT01309698
completedphase_4

Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

NCT02049814
completed

Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"

NCT01993927
terminatednot_applicable

Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT

NCT00212017
completedphase_3

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

NCT00837577
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT01309698Phase 4

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Completed
NCT02049814Phase 4

Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

Completed
NCT01993927

Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"

Completed
NCT00212017Not Applicable

Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT

Terminated
NCT00837577Phase 3

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

Completed
NCT02097342Phase 4

Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus

Unknown
NCT00654381Phase 3

Japanese P III vs Voglibose and Placebo

Completed
NCT00663884Phase 4

Glufast On Insulin Glargine Trial in Type 2 DM

Completed
NCT01263470Phase 2

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan

Completed
NCT01263496Phase 2

Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan

Completed
NCT01263483Phase 2

Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11